evaluate novo nordisk on glp-1 agonists Bolsters Portfolio With OZEMPIC's New Approval Rising Demand for GLP-1 Receptor

In the paper, Banks called it troubling how easy it is to obtain a prescription for weight loss drugs and worried they might exacerbate existing eating disorders or cause new cases, including of anorexia

Deganutti, G

Exenatide extended-release has been shown in studies to cause thyroid tumors in animals, but it's not yet known if it can cause thyroid cancer in people

Cason-Wilkerson, R., Thompson, D

is supported in part by a Banting and Best Diabetes Centre Novo Nordisk Chair in Incretin Biology, and a Sinai Health Novo Nordisk Foundation Fund in Regulatory Peptides

4,6 A key issue in the physiology of type 2 diabetes (T2DM) is the reduced incretin effect, which mainly results from decreased activity of the primary incretin hormones, GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide)